Status:
COMPLETED
Outpatient Cervical Ripening
Lead Sponsor:
Prisma Health-Upstate
Conditions:
Pregnancy
Eligibility:
FEMALE
Brief Summary
The process of labor induction can mean several hours or even days spent as an inpatient prior to delivery. These prolonged hospital admissions contribute to increased financial burden on both patient...
Detailed Description
This study will attempt to assess whether outpatient cervical ripening with misoprostol, a synthetic PGE1 analog (Cytotec(R), Pfizer), is an effective and safe option for low-risk pregnant women at or...
Eligibility Criteria
Inclusion
- Low risk, pregnant women seeking elective induction of labor after 39 weeks gestation
- Women without a medical indication for induction of labor.
- Multigravida or primigravida women who are scheduled for late term (postdates) induction will be included.
Exclusion
- Previous cesarean section,
- Any contraindication to labor or vaginal delivery,
- A ny patients where misoprostol should be used with caution (IUGR, oligohydramnios)
- Bishop score \> 6
- ruptured amnioticmembranes
Key Trial Info
Start Date :
June 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2020
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT04041687
Start Date
June 1 2019
End Date
March 1 2020
Last Update
October 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prisma Health
Greenville, South Carolina, United States, 29605